EMA und FDA sind uneins | PZ – Pharmazeutische Zeitung
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently | SpringerLink
IJMS | Free Full-Text | SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
SGLT2-Inhibitoren zur Therapie des Typ-2-Diabetes
Neue Diabetemedikamente Typ-2-Diabetes - diabetes-news : diabetes-news
SGLT inhibitors in management of diabetes - The Lancet Diabetes & Endocrinology
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
SGLT-2-Hemmer zur Diabetes-Behandlung
BVKD – Die Diabetes-Kliniken - Ketoazidose unter SGLT2-Blockern • diabetologie-online
SGLT-1/2-Hemmer auch bei Typ-1-Diabetes? - Der niedergelassene Arzt
SGLT2-Inhibitoren - 05 - 2015 - Heftarchiv - AMT
SGLT-2 and the genesis of hyperfiltration - Renal Fellow Network
SGLT2-Hemmer in der Therapie des Diabetes Typ 2 - YouTube
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis - The Lancet Diabetes & Endocrinology
The evolving role of SGLT2 inhibitors - DiabetesontheNet
News
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care | Diabetes Technology & Therapeutics
SciELO - Brazil - SGLT-2 inhibitors in diabetes: a focus on renoprotection SGLT-2 inhibitors in diabetes: a focus on renoprotection
SGLT2 Inhibitors and Adverse Events: A Closer Look – AJKD Blog
SGLT2 Inhibitors: The Future is Flozin! | BROWN MED-PEDS RESIDENCY
JCM | Free Full-Text | SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
The role of SGLT, NHE, and their inhibitors in diabetes and... | Download Scientific Diagram
PharmaWiki - SGLT2-Hemmer
